Free Samples and Fillers: No Teaching Away or Commercial Success
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Kenneth McNeill & Daniel P. Hughes
INCEPT LLC v. PALETTE LIFE SCIENCES, INC.
Before Newman, Schall, and Taranto. Appeal from the Patent Trial and Appeal Board.
Summary: No teaching away when art does not disparage invention and free samples cannot count as commercial success.
Palette requested Inter Partes review of patents owned by Incept. The patents at issue claimed introducing a biodegradable filler between a radiation target tissue and other tissue to decrease the amount of radiation received by the non-targeted tissue. Palette argued that some claims at issue were anticipated by the prior art reference Wallace and other claims were obvious in light of Wallace. Incept argued that Wallace taught away from the claimed inventions because Wallace taught that its fillers were “essentially nondegradable” over at least several months. Incept also argued that its commercial success in selling a covered product showed the claims were not obvious. The PTAB found that Wallace anticipated the claimed invention and did not teach away because a teaching that a filler was nondegradable over several months implied that the filler was degradable after several months. The PTAB also rejected Incept’s commercial success arguments because the sales data that Incept relied on included free samples.
The Federal Circuit affirmed the Board’s decision. The Federal Circuit agreed that Wallace did not teach away because it did not disparage or discredit using biodegradable filters and instead implied that the fillers were biodegradable. The Federal Circuit also affirmed the Board’s decision that Incept did not provide sufficient evidence of commercial success.
Judge Newman dissented in part, arguing that Wallace did not describe all limitations of the claims. Newman further argued that the Board errored by disregarding Incept’s evidence of commercial success.
Editor: Paul Stewart
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…